SINGLE CELL MUTATIONAL ANALYSIS OF PIK3CA IN CIRCULATING TUMOR CELLS AND METASTASES IN BREAST CANCER REVEALS HETEROGENEITY, DISCORDANCE, AND MUTATION PERSISTENCE IN CULTURED DISSEMINATED
Tìm thấy 14 tài liệu liên quan tới tiêu đề "SINGLE CELL MUTATIONAL ANALYSIS OF PIK3CA IN CIRCULATING TUMOR CELLS AND METASTASES IN BREAST CANCER...":
PIK3CA mutation is a favorable prognostic factor in esophageal cancer: Molecular profile by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissue
Mutational analysis by TSACP
Mutation analysis was not successful in eight cases be- cause of poor sample condition. Thus, data on genetic alterations were available for 126 patients. Somatic mu- tational analysis by TSACP identified 290 gene alter- ations, including single nucleotide variants, de[r]
Mutation analysis was not successful in eight cases be- cause of poor sample condition. Thus, data on genetic alterations were available for 126 patients. Somatic mu- tational analysis by TSACP identified 290 gene alter- ations, including single nucleotide variants, de[r]
PROSPECTIVE PHASE II TRIAL OF EVEROLIMUS IN PIK3CA AMPLIFICATION/MUTATION AND/OR PTEN LOSS PATIENTS WITH ADVANCED SOLID TUMORS REFRACTORY TO STANDARD THERAPY
We designed a single-arm, open-label phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy. The study did not meet its primary objective of demonstrating the anti-tumor activity of everolimus in PIK3CA amplif[r]
SUCCESSFUL CONTROL OF HEAVILY PRETREATED METASTATIC GASTRIC CANCER WITH THE MTOR INHIBITOR EVEROLIMUS (RAD001) IN A PATIENT WITH PIK3CA MUTATION AND PS6 OVEREXPRESSION
Everolimus (RAD001) is an orally administered mTOR inhibitor that is well known for its antitumor efficacy and that has been approved for the treatment of several solid tumors, including renal cell carcinoma. In gastric cancer (GC), despite previous preclinical and phase I/II studies suggesting the[r]
6 Đọc thêm
RETROSPECTIVE STUDY OF RAS/PIK3CA/BRAF TUMOR MUTATIONS AS PREDICTORS OF RESPONSE TO FIRST-LINE CHEMOTHERAPY WITH BEVACIZUMAB IN METASTATIC COLORECTAL CANCER PATIENTS
After analysis of minor RAS mutations (KRAS exon 3, 4/NRAS) in the FIRE-3 and PRIME studies, an expanded range of RAS mutations were established as a negative predictive marker for the efficacy of anti-EGFR antibody treatment. BRAF and PIK3CA mutations may be candidate biomarkers for anti-EGFR targe[r]
PIK3CA DEPENDENCE AND SENSITIVITY TO THERAPEUTIC TARGETING IN UROTHELIAL CARCINOMA
Many urothelial carcinomas (UC) contain activating PIK3CA mutations. In telomerase-immortalized normal urothelial cells (TERT-NHUC), ectopic expression of mutant PIK3CA induces PI3K pathway activation, cell proliferation and cell migration.
12 Đọc thêm
MICROSATELLITE INSTABILITY AND MUTATIONS IN BRAF AND KRAS ARE SIGNIFICANT PREDICTORS OF DISSEMINATED DISEASE IN COLON CANCER
Molecular alterations are well studied in colon cancer, however there is still need for an improved understanding of their prognostic impact. This study aims to characterize colon cancer with regard to KRAS, BRAF, and PIK3CA mutations, microsatellite instability (MSI), and average DNA copy number, i[r]
HIGH EGFR PROTEIN EXPRESSION AND EXON 9 PIK3CA MUTATIONS ARE INDEPENDENT PROGNOSTIC FACTORS IN TRIPLE NEGATIVE BREAST CANCERS
Triple negative breast cancers (TNBC) are a more aggressive subset of breast cancer. A better understanding of its biology could allow the rational development of targeted therapies. High EGFR protein expression and exon 9 PIK3CA activating mutations are independent prognostic factors in TNBC. The e[r]
10 Đọc thêm
A RETROSPECTIVE OBSERVATIONAL STUDY OF CLINICOPATHOLOGICAL FEATURES OF KRAS, NRAS, BRAF AND PIK3CA MUTATIONS IN JAPANESE PATIENTS WITH METASTATIC COLORECTAL CANCER
The mutation in KRAS exon 2 is a validated biomarker of resistance to anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer (mCRC). Several reports have confirmed associations of other RAS mutations with resistance to anti-EGFR therapy. However, the impact of BRAF and[r]
PROGNOSTIC AND CLINICAL IMPACT OF PIK3CA MUTATION IN GASTRIC CANCER: PYROSEQUENCING TECHNOLOGY AND LITERATURE REVIEW
Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) mutations that activate the PI3K/AKT signaling pathway have been observed in several types of carcinoma and have been associated with patient prognosis.
Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer
The relationships among PIK3CA mutations, medication use and tumor progression remains poorly understood. Aspirin use post-diagnosis may modify components of the PI3K pathway, including AKT and mTOR, and has been associated with lower risk of breast cancer recurrence and mortality.
BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients
Mutations in KRAS, BRAF and PIK3CA are the most common somatic alterations found in the colorectal cancer (CRC) patients from Western countries; but their prevalence and prognostic value have not been adequately assessed in Asian patients.
ĐỀ THI DƯỢC LIỆU 1 THAM KHẢO
CHƯƠNG 1: ĐẠI CƯƠNG VỀ DƯỢC LIỆUI TRẮC NGHIỆM1. Ai được suy tôn là tổ sư ngành y học hiên đại phương Tây:A. Hyppocrates (Yh Hy lạp)B. Celus(Yh. La Mã)C. Dioscorides(Yh. La Mã)D. Galen(Yh. La Mã)2. Chọn câu SAI A. Thời Trung Cổ (5751300)đB. Thời Cận Đại (17071778)sC. Thời Phục Hưng (13001650)đD.[r]
ĐỒ ÁN TỐT NGHIỆP - CHƯƠNG 7: TÍNH XÂY DỰNG
Đồ án tốt nghiệp 1 GVHD: Trương Thị Minh Hạnh Chương 7TÍNH XÂY DỰNG7.1. Tính nhân lực lao động7.1.1. Chế độ làm việc của nhà máyDo điều kiện khí hậu ở nước ta chỉ thuận lợi cho việc trồng mía và thu hoạch theo mùa. Do đó, các nhà máy đường đều sản xuất theo mùa vụ, mỗi vụ khoảng 6 đến 7 tháng, từ th[r]
11 Đọc thêm
